Propanc Biopharma is Testing Life-Altering Cancer Treatment: CEO

Our proenzyme cancer therapy may have a significant impact on a patient’s survival, says Propanc Biopharma Inc CEO James Nathanielsz


In this interview, SmallCapPower speaks with James Nathanielsz, CEO of Propanc Biopharma Inc, which is a clinical-stage biopharmaceutical company developing a new treatment for metastatic cancer. Propanc Biopharma’s cancer therapy uses proenzymes from the pancreas to halt the ability of cancer cells to spread and recur. This new frontier in cancer therapy is targeted for patients suffering from pancreatic, ovarian and colorectal cancers. According to James Nathanielsz, an added benefit of the Company’s treatment is that it doesn’t cause the typical side effects of standard treatments such as nausea, hair loss or a suppressed immune system.

To read our full disclosure, please click on the button below: